Multistage drug effects of ketamine in the treatment of major depression
- PMID: 25217177
- DOI: 10.1007/s00406-014-0535-3
Multistage drug effects of ketamine in the treatment of major depression
Abstract
A substantial number of patients diagnosed with major depression disorder show poor or no response to standard antidepressive drugs. Recent studies showed that ketamine promotes a rapid and sustained antidepressive effect in treatment-resistant depression. Importantly, after a single dose, such antidepressant action appears very fast, reaching maximum efficacy after 1-2 days before it slowly decays after 3-7 days. This temporal pattern is especially interesting since most effects are investigated following single, subanesthetic doses. This means that effects are observed at time points when the blood levels have long fallen below any active threshold. Mechanisms of action thus may be sought either in secondary or compensatory processes, which develop after acute systemic derangement or in molecular downstream mechanisms of action, which after initiation do not require the presence of active drug levels. We here review acute and delayed effects of subanesthetic ketamine infusion and discuss potential origins of antidepressant drug action. We will provide evidences that both acute effects on abnormal network configuration and delayed effects at the level of homeostatic synaptic plasticity may be necessary for antidepressant action. We further argue that such effects should be followed by a temporally well-defined exploitation of these transient changes by therapeutic processes, aiming at sustained changes of network configuration via psychotherapeutic or other methods.
Similar articles
-
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10. J Affect Disord. 2014. PMID: 24388038 Review.
-
The Ketamine Antidepressant Story: New Insights.Molecules. 2020 Dec 7;25(23):5777. doi: 10.3390/molecules25235777. Molecules. 2020. PMID: 33297563 Free PMC article. Review.
-
Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.Biol Psychiatry. 2016 Sep 15;80(6):457-468. doi: 10.1016/j.biopsych.2016.02.009. Epub 2016 Feb 13. Biol Psychiatry. 2016. PMID: 27062563 Free PMC article.
-
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.Neuropsychopharmacology. 2015 Mar 13;40(5):1084-90. doi: 10.1038/npp.2014.298. Neuropsychopharmacology. 2015. PMID: 25374095 Free PMC article. Clinical Trial.
-
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.Biol Psychiatry. 2010 Jan 15;67(2):139-45. doi: 10.1016/j.biopsych.2009.08.038. Biol Psychiatry. 2010. PMID: 19897179 Clinical Trial.
Cited by
-
The Risk of Upper Urinary Tract Involvement in Patients With Ketamine-Associated Uropathy.Int Neurourol J. 2017 Jun;21(2):128-132. doi: 10.5213/inj.1732704.352. Epub 2017 Jun 21. Int Neurourol J. 2017. PMID: 28673061 Free PMC article.
-
Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities.Neuropsychopharmacology. 2017 May;42(6):1201-1209. doi: 10.1038/npp.2016.184. Epub 2016 Sep 8. Neuropsychopharmacology. 2017. PMID: 27604568 Free PMC article. Clinical Trial.
-
Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression.Psychopharmacology (Berl). 2016 Feb;233(3):405-15. doi: 10.1007/s00213-015-4128-2. Epub 2015 Oct 29. Psychopharmacology (Berl). 2016. PMID: 26514555
-
Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation.Hum Brain Mapp. 2016 May;37(5):1941-52. doi: 10.1002/hbm.23148. Epub 2016 Feb 25. Hum Brain Mapp. 2016. PMID: 26915535 Free PMC article.
-
Default mode network connectivity change corresponds to ketamine's delayed glutamatergic effects.Eur Arch Psychiatry Clin Neurosci. 2020 Mar;270(2):207-216. doi: 10.1007/s00406-018-0942-y. Epub 2018 Oct 23. Eur Arch Psychiatry Clin Neurosci. 2020. PMID: 30353262 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources